Contact

info@syndevrx.com

1 Broadway # 14, Cambridge, MA 02142

QUT SDX Collaboration Press Release 07Dec 2021
– Part of an ongoing investigation focused on how obesity and dysregulated metabolic hormones promote prostate cancer progression and metastasis
– Studies aim to quantify the ability of SynDevRx MetAP2 inhibitor evexomostat (SDX-7320) to control tumor growth of castration resistant prostate cancers